197 related articles for article (PubMed ID: 31216925)
1. EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia.
Kosalai ST; Morsy MHA; Papakonstantinou N; Mansouri L; Stavroyianni N; Kanduri C; Stamatopoulos K; Rosenquist R; Kanduri M
Epigenetics; 2019 Nov; 14(11):1125-1140. PubMed ID: 31216925
[TBL] [Abstract][Full Text] [Related]
2. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N; Ntoufa S; Chartomatsidou E; Kotta K; Agathangelidis A; Giassafaki L; Karamanli T; Bele P; Moysiadis T; Baliakas P; Sutton LA; Stavroyianni N; Anagnostopoulos A; Makris AM; Ghia P; Rosenquist R; Stamatopoulos K
Oncotarget; 2016 Jun; 7(24):35946-35959. PubMed ID: 27191993
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.
Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M
Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
5. EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes.
Szurián K; Csala I; Marosvári D; Rajnai H; Dezső K; Bödör C; Piurkó V; Matolcsy A; Reiniger L
Exp Mol Pathol; 2018 Oct; 105(2):161-165. PubMed ID: 30031020
[TBL] [Abstract][Full Text] [Related]
6. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
7. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
8. Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis.
Cheng T; Xu Y
Med Sci Monit; 2018 Oct; 24():7249-7255. PubMed ID: 30305602
[TBL] [Abstract][Full Text] [Related]
9. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3 target gene profile highlights differences between low- and high-grade astrocytic tumors.
Sharma V; Malgulwar PB; Purkait S; Patil V; Pathak P; Agrawal R; Kulshreshtha R; Mallick S; Julka PK; Suri A; Sharma BS; Suri V; Sharma MC; Sarkar C
Carcinogenesis; 2017 Feb; 38(2):152-161. PubMed ID: 27993893
[TBL] [Abstract][Full Text] [Related]
11. Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA.
Kumari K; Das B; Adhya A; Chaudhary S; Senapati S; Mishra SK
Cell Death Dis; 2018 Feb; 9(2):152. PubMed ID: 29396474
[TBL] [Abstract][Full Text] [Related]
12. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
[TBL] [Abstract][Full Text] [Related]
13. Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing.
Li Y; Luo M; Shi X; Lu Z; Sun S; Huang J; Chen Z; He J
Oncotarget; 2016 Dec; 7(49):81715-81726. PubMed ID: 27835578
[TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.
Scialdone A; Hasni MS; Damm JK; Lennartsson A; Gullberg U; Drott K
Oncotarget; 2017 Jun; 8(23):37409-37422. PubMed ID: 28445158
[TBL] [Abstract][Full Text] [Related]
15. EZH2 mitigates the cardioprotective effects of mesenchymal stem cell-secreted exosomes against infarction via HMGA2-mediated PI3K/AKT signaling.
Jiao W; Hao J; Xie Y; Meng M; Gao W
BMC Cardiovasc Disord; 2022 Mar; 22(1):95. PubMed ID: 35264108
[TBL] [Abstract][Full Text] [Related]
16. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
17. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
18. Androgens Regulate Ovarian Gene Expression Through Modulation of Ezh2 Expression and Activity.
Ma X; Hayes E; Biswas A; Seger C; Prizant H; Hammes SR; Sen A
Endocrinology; 2017 Sep; 158(9):2944-2954. PubMed ID: 28666321
[TBL] [Abstract][Full Text] [Related]
19. Silencing IGF-II impairs C-myc and N-ras expressions of SMMC-7721 cells via suppressing FAK/PI3K/Akt signaling pathway.
Ji Y; Wang Z; Li Z; Huang N; Chen H; Li B; Hui B
Cytokine; 2017 Feb; 90():44-53. PubMed ID: 27768959
[TBL] [Abstract][Full Text] [Related]
20. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]